Aspira Women's Health Files 8-K

Ticker: AWHL · Form: 8-K · Filed: Oct 23, 2024 · CIK: 926617

Aspira Women'S Health INC. 8-K Filing Summary
FieldDetail
CompanyAspira Women'S Health INC. (AWHL)
Form Type8-K
Filed DateOct 23, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.001, $10 million
Sentimentneutral

Sentiment: neutral

Topics: 8-K, filing, company-information

TL;DR

Aspira Women's Health filed an 8-K on 10/23/24. Standard disclosure.

AI Summary

Aspira Women's Health Inc. filed an 8-K on October 23, 2024, reporting other events and financial statements. The company, formerly known as Vermillion, Inc., Ciphergen Biosystems Inc., and Abiotic Systems, is incorporated in Delaware and headquartered in Austin, Texas.

Why It Matters

This filing indicates that Aspira Women's Health Inc. has made official disclosures regarding company events and financial information to the SEC.

Risk Assessment

Risk Level: low — This is a routine filing of an 8-K, which typically reports significant events or financial updates, but the content itself doesn't indicate immediate high risk.

Key Numbers

Key Players & Entities

FAQ

What specific 'Other Events' are being reported in this 8-K filing?

The provided text is a header and does not detail the specific 'Other Events' being reported, only that this item is included.

What is the primary business of Aspira Women's Health Inc.?

Aspira Women's Health Inc. is in the business of 'IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES' as indicated by its Standard Industrial Classification code.

When did Aspira Women's Health Inc. change its name from Vermillion, Inc.?

The filing indicates the name change from Vermillion, Inc. occurred on August 24, 2007.

What is the fiscal year end for Aspira Women's Health Inc.?

The fiscal year end for Aspira Women's Health Inc. is December 31st.

What is the physical address of Aspira Women's Health Inc.?

The business address is 12117 Bee Caves Road, Building Three, Suite 100, Austin, TX 78738.

Filing Stats: 457 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2024-10-23 13:29:26

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Aspira Women's Health Inc. Date: October 23, 2024 By: /s/ Nicole Sandford Nicole Sandford, Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing